Hereditary Angioedema Prophylaxis
Pharvaris Netherlands B.V. focuses on preventive treatment strategies for hereditary angioedema, with research centred on reducing the frequency of swelling attacks in adults and adolescents living with C1 inhibitor deficiency.
- Long-term prophylactic therapy
- Attack prevention in HAE
- Oral treatment for recurrent angioedema
Its clinical portfolio includes work in both HAE due to C1-inhibitor deficiency and broader hereditary angioedema populations.
On-Demand Angioedema Treatment
The sponsor also investigates therapies intended for immediate use during acute angioedema attacks, including treatment of symptomatic episodes in hereditary angioedema and laryngeal attacks.
- Rapid symptom relief during attacks
- Acute attack management
- Self-administered oral therapy
Research in this area spans both adults and adolescents, with attention to episodic disease control.
Acquired Angioedema Research
Pharvaris Clinical extends its work to acquired angioedema due to C1 inhibitor deficiency, examining treatment options for both prevention and on-demand control of swelling episodes.
- AAE-C1INH prophylaxis
- On-demand relief for acquired angioedema
- Safety and tolerability in recurrent attacks
This area reflects interest in complement-mediated angioedema beyond inherited disease forms.
Oral Deucrictibant Development
The sponsor’s clinical programme is built around deucrictibant and PHA-022121, with research covering both extended-release formulations and soft capsule presentations for angioedema management.
- Extended-release oral formulations
- Prophylactic and on-demand use
- Pharmacokinetics and formulation performance
Related studies include evaluation in healthy volunteers to support oral delivery and treatment consistency.
